CVS健康
CVS
92.36
-0.22
-0.24%
CVS健康
US · CVS
#168 按市值排名
上市于 1970
92.36
-0.22
-0.24%
实时 - 追踪5344个代码 - 心跳于409秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了11家。
- 机构持股总比例下降了0.3个百分点。
机构持股
- 机构持股比例
- 90.27% -0.27pp
- 机构数量
- 2,347 -11
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund76.83%
Public Company4.12%
Hedge Fund3.28%
Government Pension Fund2.05%
Sovereign Wealth Fund1.52%
Private Company1.50%
Insurance Company0.51%
Family Office/Trust0.20%
Government0.10%
Other9.88%
主要股东 截至 2026-06-30
BlackRock
9.63% · 123.22M 股
Capital Research
9.05% · 115.79M 股
Vanguard Capital Management, LLC
7.07% · 90.48M 股
State Street Global Advisors
4.71% · 60.28M 股
Dodge & Cox
3.91% · 50.01M 股
Other
65.61%
Wellington Management Group
2.64% · 33.80M 股
Geode Capital Management, LLC
2.34% · 29.90M 股
Vanguard Portfolio Management, LLC
2.08% · 26.64M 股
T. Rowe Price Group, Inc.
1.89% · 24.21M 股
FMR
1.79% · 22.95M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 30次买入 · 20次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Karen Lynch | Chief Executive Officer | 0.04% |
| C. Brown | Independent Director | 0.01% |
| Jean-Pierre Millon | Independent Director | 0.01% |
| J. Joyner | Executive Vice President & President of CVS Caremark | 0.01% |
| Prem Shah | Executive VP, Chief Pharmacy Officer and President of Pharmacy & Consumer Wellness | 0.01% |
| Michael Mahoney | Director | 0.00% |
| Nancy-Ann DeParle | Independent Director | 0.00% |
| Samrat Khichi | Executive VP, Chief Policy Officer & General Counsel | 0.00% |
| James Clark | Chief Accounting Officer | 0.00% |
| Anne Finucane | Independent Director | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-06-25 | James Clark | Chief Accounting Officer | Sale to Issuer | -454 | $90.98 |
| 2026-05-30 | Amy Compton-Phillips | Chief Medical Officer | Sale to Issuer | -7,618 | $90.98 |
| 2026-05-30 | Brian Newman | Chief Financial Officer | Sale to Issuer | -2,478 | $90.98 |
| 2026-05-20 | Roger Farah | Independent Chairperson | Intent to Sell (Form 144) | -2,817 | $93.68 |
| 2026-05-20 | Fernando Aguirre | Independent Director | Sale to Issuer | -32,000 | $93.50–93.78 |
| 2026-05-20 | Glenview Capital Management, LLC | -- | Open Market Disposition | -3,372,000 | $93.45–96.28 |
| 2026-05-20 | Glenview Capital Management, LLC | -- | Open Market Derivative Dispositi | -378,000 | $58.29 |
| 2026-05-19 | Fernando Aguirre | Independent Director | Intent to Sell (Form 144) | -32,000 | $94.69 |
| 2026-05-13 | Douglas Shulman | Director | Other Derivative Acquisition | +1,447 | -- |
| 2026-05-13 | J. Kirby | Director | Other Acquisition | +1,447 | $97.15 |
| 2026-05-13 | Lawrence Robbins | Director | Other Derivative Acquisition | +1,930 | -- |
| 2026-05-13 | Anne Finucane | Independent Director | Other Derivative Acquisition | +1,544 | -- |
| 2026-05-13 | C. Brown | Independent Director | Other Acquisition | +1,544 | $97.15 |
| 2026-05-13 | Alecia DeCoudreaux | Independent Director | Other Derivative Acquisition | +1,447 | -- |
| 2026-05-13 | Guy Sansone | Director | Other Acquisition | +1,447 | $97.15 |
| 2026-05-13 | Fernando Aguirre | Independent Director | Other Acquisition | +1,563 | $97.15 |
| 2026-05-13 | Jeffrey Balser | Independent Director | Other Acquisition | +2,058 | $97.15 |
| 2026-05-13 | Leslie Norwalk | Director | Other Acquisition | +1,447 | $97.15 |
| 2026-05-13 | John Gallina | Director | Other Derivative Acquisition | +1,447 | -- |
| 2026-05-13 | Michael Mahoney | Director | Other Derivative Acquisition | +1,737 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:34 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
CVS健康 讨论区 0 条评论